- Recent Funding
- Investors
- OrbiMed
OrbiMed portfolio
OrbiMed has 22 portfolio companies on record at Recent Funding, with 8 investments in the last 12 months.
About this page
It is a crossover fund based in New York, US, founded in 1989. It led 10 of the 32 rounds it joined. Its most recent investment on record is Dren Bio's $350M funding round in October 2026, alongside Taiho Ventures, General Catalyst, HBM Healthcare Investments and 6 others. By category, its portfolio leans toward Health and bio (22) and Consumer and social (2). It has co-invested with SR One, RA Capital Management and Cormorant Asset Management, most often SR One (6 rounds).
About OrbiMed
Fund returns
| Fund | Vintage | Size | Net IRR | TVPI | DPI | As of |
|---|---|---|---|---|---|---|
| OrbiMed Private Investments IX, LP | 2022 | — | 29.3% | 1.16x | 0.21x | Sep 30, 2025 |
| OrbiMed Royalty & Credit Opportunities IV | 2022 | — | 14.1% | 1.28x | 0.25x | Sep 30, 2025 |
| OrbiMed Royalty & Credit Opportunities III, LP | 2019 | — | 15.1% | 1.20x | 0.95x | Jun 30, 2025 |
| Orbimed Private lnvesuncnts IV, L P | 2009 | — | 36.2% | 2.67x | 0.45x | Jun 30, 2016 |
| Orbimed Private Investments III, LP | 2006 | — | 18.1% | 2.34x | 1.48x | Dec 31, 2016 |
| Orbimed Private lnvesunents Ill, LP | 2006 | — | 18.4% | 2.32x | — | Jun 30, 2016 |
What OrbiMed invests in
- Health and bio · 22 · 100%
- Consumer and social · 2 · 9%
- Data and analytics · 2 · 9%
- Education · 1 · 5%
- Commerce and retail · 1 · 5%
OrbiMed recent investments
| Company | Round | Date | Alongside |
|---|---|---|---|
| round · $350M | Taiho Ventures, General Catalyst, HBM Healthcare Investments +6 | ||
| Series B+ · $200M · lead | Redmile Group, Janus Henderson Investors (lead), Catalio +6 | ||
| Series B+ · $67.4M | Windham Venture Partners, Wellington Management, Novartis Venture Fund +6 | ||
| Series B+ · $89M | Hankang Capital, Qiming Venture Partners, Logos Capital +4 | ||
| Series B+ · $130M | Venrock Healthcare Capital Partners (lead), Wellington Management, Morningside +6 | ||
| Series A · $82M · lead | 5AM Ventures (lead), Wing VC, Lux Capital +1 | ||
| Series A · $200M | Longitude Capital, Goldman Sachs Alternatives, SR One +2 | ||
| Series B+ · $115M · lead | LYFE Capital, Kite Pharma, Lifeforce Capital +6 |
How OrbiMed invests
OrbiMed portfolio companies
DDren Bio$350Mround · Oct 2026SStar Therapeutics$200MSeries B+ · Oct 2026
FFore Biotherapeutics$67.4MSeries B+ · Jul 2026
PPinnacle Medicines$89MSeries B+ · Mar 2026
AAngitia Bio$130MSeries B+ · Feb 2026
MMendra$82MSeries A · Jan 2026AAirNexis Therapeutics$200MSeries A · Jan 2026
AAspen Neuroscience$115MSeries B+ · Nov 2025
TTreeline Biosciences$200MSeries A · Sep 2025
PProVerum$80MSeries B+ · Aug 2025
RRayThera$110MSeries A · Apr 2025
WWindward Bio$200MSeries A · Jan 2025
VVerdiva Bio$410MSeries A · Jan 2025
KKapiva$10MSeries B+ · Sep 2024
MMirador Therapeutics$400MSeries A · Mar 2024
NNoctrix Health$40MSeries B+ · Jan 2024
KKoya Medical$30MSeries B+ · Nov 2023
AAmolyt Pharma$140MSeries B+ · Jan 2023
MMdclone$63MSeries B+ · Mar 2022
LLaekna Therapeuticsbacker
CCurevo Vaccinebacker
HHelicorebacker
| Company | Round with OrbiMed | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
round · $350M | $415M | Oct 29, 2026 round |
Health and bio |
Series B+ · $200M · lead | $415M | Oct 23, 2026 Series B+ |
Health and bio |
Series B+ · $67.4M | $182.4M | Jul 8, 2026 Series B+ |
Health and bio |
Series B+ · $89M | $89M | Mar 26, 2026 Series B+ |
Health and bio |
Series B+ · $130M | $130M | Feb 12, 2026 Series B+ |
Health and bio |
Series A · $82M · lead | $82M | Jan 29, 2026 Series A |
Health and bio |
Series A · $200M | $200M | Jan 9, 2026 Series A |
Health and bio |
Series B+ · $115M · lead | $339M | Nov 20, 2025 Series B+ |
Health and bio |
Series A · $200M | $461M | Sep 3, 2025 Series A |
Health and bio |
Series B+ · $80M | $118.16M | Aug 25, 2025 Series B+ |
Health and bio |
Series A · $110M · lead | $110M | Apr 4, 2025 Series A |
Health and bio |
Series A · $200M · lead | $200M | May 5, 2026 round |
Health and bio |
Series A · $410M | $410M | Jan 9, 2025 Series A |
Health and bio |
Series B+ · $10M · lead | $70M | Sep 29, 2025 Series B+ |
Health and bio |
Series A · $400M · lead | $650M | Jan 13, 2026 Series B+ |
Health and bio |
Series B+ · $40M | $73.5M | Sep 2, 2025 round |
Health and bio |
Series B+ · $30M · lead | $56M | Nov 15, 2023 Series B+ |
Health and bio |
Series B+ · $140M | $294M | Jan 6, 2023 Series B+ |
Health and bio |
Series B+ · $63M | $99M | Mar 1, 2022 Series B+ |
Health and bio |
backer | $61M | May 18, 2022 Series B+ |
Health and bio |
backer | undisclosed | Mar 18, 2025 Series B+ |
Health and bio |
backer | undisclosed | Jan 28, 2025 Series A |
Most frequent co-investors
SSR One6 shared rounds · last Oct 29, 2026
RRA Capital Management6 shared rounds · last Oct 23, 2026
CCormorant Asset Management5 shared rounds · last Oct 29, 2026
AARCH Venture Partners5 shared rounds · last Sep 3, 2025
LLightspeed4 shared rounds · last Oct 29, 2026
SSofinnova Partners4 shared rounds · last Oct 23, 2026
WWellington Management4 shared rounds · last Jul 8, 2026
SS324 shared rounds · last Nov 20, 2025
RRedmile Group3 shared rounds · last Oct 23, 2026
JJanus Henderson Investors3 shared rounds · last Oct 23, 2026
NNYBC Ventures3 shared rounds · last Oct 23, 2026
SSoleus Capital3 shared rounds · last Oct 23, 2026
Similar investors
MMirae Asset Capital22 companies · 9 deals in 12 mo
EEverywhere Ventures22 companies · 3 deals in 12 mo
OObvious Ventures22 companies · 3 deals in 12 mo
EEmerson Collective23 companies · 6 deals in 12 mo
EEuropean Investment Bank Group23 companies · 5 deals in 12 mo
EEarlybird VC23 companies · 2 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Net returns as reported by the public-pension and foundation LPs invested in each fund.
Firm profile and fund returns: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 32 rounds on Recent Funding that name OrbiMed. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists OrbiMed, which is a subset of its real portfolio. API: /api/v1/investors/orbimed (get a free API key). More: the most active VC firms and new venture capital funds.
The week's top funded startups and market insights, in your inbox every Monday.
Unsubscribe anytime · privacy